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 Chapter 21 
 Murine GLUTag Cells 
 Manuel  Gil-Lozano and  Patricia  L.  Brubaker 
 Abstract  The incretin hormone, glucagon-like peptide-1 (GLP-1) serves as a link 
between ingested nutrients and insulin secretion. Because of the anti-diabetic prop-
erties exerted by GLP-1, several derivative drugs are currently in the market for the 
treatment of patients with type 2 diabetes. Over the past few years, several cell lines 
have been established as useful models for the study of the GLP-1- secreting entero-
endocrine L-cells. This review focuses on the murine GLUTag cell line, derived 
from colonic tumours of transgenic mice expressing large T antigen under the control 
of the  proglucagon promoter. These cells are widely used to examine the effects of 
food components on GLP-1 secretion, as well as the signaling pathways underlying 
nutrient-induced GLP-1 release. The effects of different food components, as well 
as of nutrient-related signals, on GLP-1 secretion, and the protocols for the mainte-
nance and use of the murine GLUTag L-cell line will be discussed. 
 Keywords  Cell line •  Cell culture •  Endocrine hormone •  Enteroendocrine •  Food 
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 Secretion 
21.1  Introduction 
 The potent insulinotrophic activity of the intestinal hormone, glucagon-like 
peptide-1 (GLP-1), in the perfused rat pancreas was fi rst described almost 30 years 
ago. This fi nding was rapidly followed by the demonstration that physiological lev-
els of the peptide also stimulate insulin secretion in a glucose-dependent manner in 
humans. Since then, our knowledge of the physiological effects of GLP-1 has vastly 
increased and several anti-diabetic properties such as suppression of glucagon 
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secretion, induction of satiety, reduction of gastric activity and potentiation of pan-
creatic β-cell mass have also been attributed to the peptide. Overall, these effects made 
GLP-1 a promising novel therapeutic tool for the treatment of type 2 diabetes mel-
litus, and GLP-1 derivative drugs have been successfully used to reduce glycemia 
in patients with type 2 diabetes since 2005. These anti-diabetic agents include ago-
nists of the GLP-1 receptor long-lasting analogues of the native peptide and inhibi-
tors of the enzyme responsible for the rapid degradation of the active forms of 
GLP-1 (Dong and Brubaker  2012 ). Interestingly, potentiation of the endogenous 
secretion of the peptide is another possible therapeutic approach which has gained 
much attention lately; however, a better understanding of the processes regulating 
GLP-1 secretion by the intestinal L-cell (an enteroendocrine type of cell which is 
the major source of circulating GLP-1 in the body) is still required. 
 Over the past few years, the establishment of different enteroendocrine cell lines 
has markedly improved our understanding of the different signals that modulate 
GLP-1 expression and secretion, as well as the intracellular pathways activated by 
these signals. The use of cell lines has also helped to troubleshoot the inherent diffi cul-
ties derived from the use of intestinal primary cell cultures, such as low L-cell density 
and a high risk of bacterial contamination. Among all cell line models for the study of 
GLP-1 secretion, the murine GLUTag cells are the most widely used as well as the 
most specifi c. Thus, GLUTag cells not only have been demonstrated to appropriately 
respond to the same stimuli that trigger GLP-1 secretion in vivo, but they also have 
been shown to closely, although not fully, mirror the profi le of genes and proteins 
expressed in non-immortalized L-cells. The present chapter will cover the modulation 
of GLP-1 secretion by the GLUTag cells, primarily focusing on the effect of food 
components, as well as the methodology for the use of this cell line. 
21.2  Origin 
 GLUTag cells derive from a colonic tumour of a transgenic mouse expressing SV40 
large T antigen under the control of approximately 2,300-base pairs of the promoter 
for  proglucagon , the gene that encodes GLP-1 amongst other bioactive peptides. 
The mice developed endocrine carcinoma of the large bowel, the cells of which 
were positive for immunoreactive GLP-1 and cholecystokinin but were negative for 
other hormones, including adrenocorticotrophin, β-endorphin, calcitonin, cortico-
trophin-releasing hormone, gastrin, growth hormone-releasing hormone, insulin, 
pancreatic polypeptide, serotonin, somatostatin and vasoactive intestinal peptide, 
suggesting an L-cell lineage for these tumour cells. Fragments of the colonic 
tumours were subcutaneously propagated in nude mice, and individual cells from 
one of these tumours were isolated and single-cell cloned (Drucker et al.  1994 ). 
The cultured cells displayed pleomorphic nuclei with prominent nucleoli, and well-
developed cytoplasmic organelles along with abundant secretory granules. GLUTag 
cells were found to express both  proglucagon and cholecystokinin transcripts. The 
cells secrete GLP-1 in response to incubation with protein kinase A and protein 
kinase C activators, whereas  proglucagon expression was only induced by 
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activators of protein kinase A, confi rming previous studies in primary cells (Drucker 
et al.  1994 ). As described for the normal intestinal L-cell, the predominant GLP-1 
form produced by the GLUTag cells is GLP-1(7-36)-amide (Drucker et al.  1994 ). 
Importantly, similar profi les in the expression of genes that encode mediators of 
nutrient-induced GLP-1 secretion, including glucokinase, sodium-glucose linked 
transporter 1 (SGLT1) and G protein-coupled receptors such as GPR40, GPR41, 
GPR119, GPR120 and GPR131 (TGR5), have been found in GLUTag and non-
immortalized L-cells (Reimann et al.  2008 ; Tolhurst et al.  2012 ). The GLUTag cells 
are thus widely considered as the best in vitro model of the murine L-cell. 
21.3  Features and Mechanisms 
21.3.1  Regulation of GLUTag Cell Secretory 
Activity by Nutrients 
 Nutrient ingestion is the most powerful mechanism for triggering GLP-1 secretion 
by the intestinal L-cell (Dong and Brubaker  2012 ). Since the L-cells are open-type 
enteroendocrine cells residing in the intestinal epithelium, with their apical surfaces 
and associated microvilli open into the gut lumen, they can directly sense and 
respond to luminal nutrients. The effects of the major groups of food components 
on GLUTag cell physiology are discussed below. 
 Carbohydrates  GLUTag cells are highly sensitive to glucose, such that cells that 
are propagated at 5 mmol/L concentration of glucose become quiescent and hyper-
polarized when this monosaccharide is removed from the medium. Accordingly, 
when glucose is added back to the bath solution, the membrane conductance 
decreases, and the frequency of action potentials in the cells, as well as the secretion of 
GLP-1 are strongly enhanced, even at very low glucose concentrations (Reimann 
and Gribble  2002 ). Initial studies demonstrated that glucose metabolism was associ-
ated with the closure of K + channels sensitive to ATP (K ATP ), resulting in increases in 
membrane conductance and enhanced GLP-1 release (Reimann and Gribble  2002 ). 
However, recent studies have indicated a more important role for a metabolism- 
independent glucose-sensing pathway in GLUTag cells (Parker et al.  2012a ). Hence, 
GLUTag cells express two sodium-glucose co-transporters, SGLT1 and SGLT3a, 
which have been found to increase glucose uptake inducing an inward current of Na+ 
ions that results in cell depolarization and stimulation of GLP-1 secretion. These 
effects are appropriately diminished by SGLT inhibitors (Parker et al.  2012a ). SGLTs 
also appear to be involved in the effects of non-metabolisable sugars, such as methyl-
α- glucopyranoside, on GLP-1 secretion by the GLUTag cell line, but not in the 
effects of dietary sugars such as fructose that are not substrates for these transporters. 
Expression of SGLT1 in the intestinal epithelium is enhanced by dietary carbohy-
drates, a process believed to be mediated by type 1 taste receptors and gustducin 
(Margolskee et al.  2007 ). Interestingly, these receptors are also expressed by the 
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GLUTag cells and they seem to mediate the effects of artifi cial sweeteners in this cell 
line, although they may not be relevant in vivo (Fujita et al.  2009 ). The facilitative 
glucose transporters, GLUT, are also involved in the stimulatory effects of glucose 
on GLP-1 secretion in the GLUTag cell line, while SGLT1 appears to be the most 
important glucose-sensing mechanism for the L-cells in vivo. The different glucose-
sensing mechanisms exhibited by GLUTag and non-immortalized L-cells may explain 
why GLUTag cells respond to small changes in glucose levels when they are incubated 
at very low concentrations of glucose (<1 mmol/L) but they are not sensitive to addi-
tional increments in glucose concentration (5–25 mmol/L; Reimann and Gribble  2002 ), 
as opposed to the dose-dependent effect of glucose in primary L-cells (Reimann et al. 
 2008 ). 
 Lipids  Free fatty acids are potent stimulators of GLUTag cell activity, the magnitude 
of the effects being proportional to their chain length (Iakoubov et al.  2007 ). 
Furthermore, GLP-1 secretion is stimulated by long-chain monounsaturated fatty 
acids, such as oleic acid, but not by similar length saturated fatty acids such as palmitic 
acid, in agreement with previous observations in primary L-cell cultures. The effects of 
oleic acid on GLP-1 secretion are known to be mediated by the atypical isozyme 
protein kinase C ζ in GLUTag cells, as also found in vivo (Iakoubov et al.  2007 ; Dong 
and Brubaker  2012 ), while a role for fatty acid transport protein 4 in the uptake of oleic 
acid by GLUTag cells has also been demonstrated (Poreba et al.  2012 ). 
 The activation of the Gq-coupled receptors, GPR40 and GPR120, by long-chain 
unsaturated fatty acids has also been associated with enhanced GLP-1 release 
in vivo (Edfalk et al.  2008 ; Hirasawa et al.  2005 ). However, although GLUTag cells 
have also been reported to express these receptors (Lauffer et al.  2009 ), their role in 
the physiology of this cell line has not been extensively studied to date. In contrast, 
the Gs-coupled receptor, GPR119, has been shown to mediate the stimulatory 
effects on GLP-1 secretion of oleoylethanolamide, an endogenously-occurring oleic 
acid derivate (Lauffer et al.  2009 ). Furthermore, synthetic GPR119 agonists have 
been found to stimulate GLP-1 secretion both in vivo and in GLUTag cells (Chu 
et al.  2008 ). Another G-protein-coupled receptor, TGR5, has also been recently 
demonstrated to play a role in the stimulatory effects of bile acids on GLP-1 secre-
tion in GLUTag cells, as previously also found in vivo (Parker et al.  2012b ; Dong 
and Brubaker  2012 ). 
 Finally, short-chain fatty acids (SCFAs), including acetate, butyrate, and propio-
nate, are generated by the gut microbiota through the digestion of complex carbohy-
drates, such as dietary fi bers. It has been recently reported that SCFAs stimulate GLP-1 
secretion via the G-protein-coupled receptor GPR43 (Tolhurst et al.  2012 ), establishing 
a novel and exciting link between gut microfl ora and gastrointestinal hormones. 
Unfortunately, the GLUTag cell line appears to be an inappropriate model to study the 
effects of SCFAs, since they express barely detectable levels of GPR43 and do not 
release GLP-1 in response to 1 or 10 mmol/L SCFAs (Tolhurst et al.  2012 ). 
 Proteins  Protein hydrolysates stimulate GLP-1 secretion and production from a 
variety of cell lines, including GLUTag cells (Hira et al.  2009 ). When the effects 
of individual amino acids were examined, several were found to stimulate GLP-1 
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secretion, with a particularly robust effect promoted by glutamine. Two major 
mechanisms have been invoked in the stimulatory effects of glutamine on GLUTag 
cells: electrogenic sodium-coupled amino acid uptake which leads to membrane 
 depolarization and voltage-gated calcium entry, and an elevation of intracellular 
cAMP levels (Tolhurst et al.  2011 ). The synergy of these two mechanisms appears 
to be a particularly strong stimulus for GLP-1 release in vitro. Other amino acids, 
such as alanine and glycine, have been found to trigger GLP-1 release from 
GLUTag cells via a pathway involving ionotrophic glycine receptors (Gameiro 
et al.  2005 ), whereas the G protein-coupled receptor family C group 6 subtype A 
receptor has been implicated in the effects on GLP-1 secretion elicited by 
 L - ornithine (Oya et al.  2013 ). 
21.3.2  Regulation of GLUTag Cell Secretory Activity 
by Other Signals 
 Despite the predominant role of nutrients in the regulation of GLP-1 release, a number 
of other signals have been identifi ed that exert stimulatory effects on the primary 
L-cell as well as on GLUTag cells. As many of these signaling mediators are induced 
by nutrient ingestion, this constitutes an indirect pathway that links food compo-
nents to the release of GLP-1. Such indirect actions are particularly important to 
GLP-1 release, since L-cells are mainly concentrated in the distal ileum and colon 
(Dong and Brubaker  2012 ), and nutrients have not reached this area of the gastroin-
testinal tract when the initial phase of prandial GLP-1 secretion is triggered. Initially, 
a neurohormonal mechanism, involving the vagus nerve, was shown to mediate the 
very rapid rise in GLP-1 levels after nutrient ingestion (Dong and Brubaker  2012 ). 
Consistent with this hypothesis, a stimulatory effect of two muscarinic agonists, 
bethanechol and carbachol, has been found in GLUTag cells (Brubaker et al.  1998 ), 
although expression of muscarinic receptors by this cell line has not been reported 
to date. Notwithstanding, direct activation of downstream protein kinase C signal-
ing does stimulate GLP-1 release from the GLUTag cells (Brubaker et al.  1998 ). 
Similarly, the incretin hormone, glucose-dependent insulinotrophic peptide (GIP), 
secreted by the enteroendocrine K cells in response to carbohydrates and fats, has 
been reported to trigger GLP-1 secretion at a concentration range of 30–100 nM 
(Brubaker et al.  1998 ). The effects of GIP on GLUTag cells are mediated through 
activation of the protein kinase A signaling pathway (Simpson et al.  2007 ). Other 
agents capable of raising the intracellular levels of cAMP, such as forskolin plus the 
cAMP phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine, have also been 
found to stimulate both GLP-1 secretion and production in GLUTag cells (Drucker 
et al.  1994 ) and are commonly used as positive controls when the secretory activity 
of this cell line is examined. Supporting the prominent role of intracellular cAMP 
levels in GLP-1 secretion, it has been reported that phosphodiesterase inhibition 
enhances the GLP-1 response to physiological secretagogues such as GIP (Simpson 
et al.  2007 ). Finally, other nutrient-dependent bioactive peptides, including leptin and 
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insulin, have also been shown to stimulate GLP-1 secretion from GLUTag cells. 
The effects of leptin are believed to be produced via activation of the Janus-activated 
kinase/signal transducers and activators of transcription signaling pathway (Anini 
and Brubaker  2003 ), whereas the effects of insulin are mediated through the activa-
tion of the extracellular signal-regulated kinases and are dependent upon the presence 
of glucose (Lim et al.  2009 ). 
21.4  Relevance to the Human Situation (L-Cell In Vivo) 
 Despite the rodent origin of GLUTag cells, they are the most extensively used in vitro 
model for the study of GLP-1 release. They have been demonstrated to respond to the 
same stimuli that trigger GLP-1 secretion in humans and they have been used to test 
potential therapeutic agents (i.e. GPR119 agonists). The diffi culties in obtaining pri-
mary L-cell cultures from humans, as well as the homogeneity of the GLUTag 
cells (i.e. single-cell clone) as compared to other L-cell models, have made GLUTag 
cells an invaluable tool for the characterization of the intra- cellular pathways that 
govern GLP-1 secretion. 
21.5  General Protocol 
21.5.1  Maintenance of the GLUTag Cell Line 
 GLUTag cells are routinely grown in Dulbecco’s Modifi ed Eagle’s Medium (DMEM) 
supplemented with 10 % fetal bovine serum (FBS), whereas supplementation with 
antibiotics, normally penicillin and streptomycin, is optional but not required. 
Cells must be trypsinized and passaged every 3–4 days when they reach 60–80 % 
confl uence. The presence of fl oating cells may be indicative of contamination or 
overgrowth. There is no standard glucose concentration to grow the cells but a fi nal 
concentration within the range 5–25 mmol/L is commonly used. It has recently been 
reported that cells grown with 25 mmol/L of glucose show increased reactive oxygen 
species production, upregulated  proglucagon , prohormone convertase 1/3 and gluco-
kinase content, and elevated basal secretion of GLP-1 as compared to cells main-
tained under 5 mmol/L conditions, suggesting enhanced metabolic activity. However, 
no difference in cell viability was found between the two conditions, and the cells 
grown with 25 mmol/L glucose were more resistant to a further metabolic insult 
(Puddu et al.  2014 ). Moreover, cells grown at either a low (5 mmol/L) or high 
(25 mmol/L) concentration of glucose have been demonstrated to respond to stim-
uli in a similar way, and no differences in GLP-1 secretion or production were 
found in cells exposed to low or high glucose for 2 h (Reimann and Gribble  2002 ), 
which is the standard incubation period to examine the GLUTag cells secretory 
response to stimuli. 
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21.5.2  Performance of Secretion and Expression Assays 
 To study the effects of different treatments on GLP-1 release (secretion assays), 
cells can be cultured in 6- or 24-well plates coated with either poly- D -lysine or 
Matrigel ® to avoid detachment of cells during the washes. A 2-day period between 
plating and the secretion assay is recommended in order to allow the cells to recover 
from trypsin and to reach the proper size and confl uence. When the cells are too 
confl uent (over 80 %), they tend to grow on top of each other, forming clumps. This 
should be avoided since it is associated with higher basal levels of secretion (per-
sonal observations). During the test period of 2 h, GLUTag cells should be main-
tained in either FBS-free DMEM or DMEM with a very low concentration of FBS 
(0.5 %), containing the treatments tested at different doses; buffers such as Krebs–
Ringer are also acceptable. To study the effects of treatments on gene expression or 
protein content, larger surface areas, such as 10 cm culture plates, may be required 
and longer incubation periods are recommended. 
 A recent study has shown that GLUTag cells possess an endogenous metabolic 
clock and that the activity of the cells can be synchronized after overnight incuba-
tion with a low concentration of FBS (0.5 %) followed by a 1-h shock with 10 % 
FBS and 10 μmol/L forskolin (Gil-Lozano et al.  2014 ). Synchronized GLUTag cells 
show a rhythm in clock genes expression as well as in their GLP-1 response to 
secretagogues, with higher responses at 4 h after synchronization and lack of effect 
at 16 h. This protocol may be adopted to obtain maximum secretory responses to a 
particular treatment. 
21.6  Assess Viability 
 Some treatments can affect viability in GLUTag cells, inducing abnormally high levels 
of GLP-1 secretion that can lead to misinterpretation of the results. Both the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and the neutral 
red uptake assays have been routinely performed in our laboratory to test the effects of 
new treatments on cell viability. Both are colorimetric assays and a reduction in absor-
bance corresponds with loss of cell viability. These tests are not quantitative and the 
addition as a reference of a positive control, such as hydrogen peroxide, is required. 
21.7  Experimental Readout of the System 
 In secretion assays, GLP-1 content in medium and cells should be determined inde-
pendently. Both medium and cell lysate should be collected and acidifi ed to ensure 
preservation of peptides and facilitate the subsequent purifi cation step. Our laboratory 
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routinely extracts peptides from the medium and cell lysate by reversed-phase 
adsorption to C18 silica columns after acidifi cation with trifl uoroacetic acid. GLP-1 
levels can then be determined by radioimmunoassay, ELISA or alternative quantifi -
cation methods. GLP-1 secretion must be calculated as the total GLP-1 content of 
the medium divided by the total GLP-1 content of medium plus cells. A ratio of 
secretion is then obtained, which can be normalized to the percentage of secretion 
of the control group. A two- to fourfold increment in secretion can be found for the 
most potent secretagogues, such as the combination of forskolin and 3-isobutyl- 1-
methylxanthine, which are often included in the study as positive controls. 
 In expression assays, medium is discarded and cells are scraped in a solution 
containing lysis buffer and β-mercaptoethanol to inactivate RNAses. Our labora-
tory has found that extraction of RNA using RNeasy Plus Mini Kit with 
QIAshredder (Qiagen, MD) permits collection of high quality RNA with a 
260/280 nm ratio over 2 and 30–100 μg of RNA per 10 cm plate. In real-time PCR 
analysis involving cDNA derived from GLUTag cells,  H3f3a amplicon (H3 his-
tone gene) is strongly recommended as an internal control, since it shows much 
better consistency than other primers commonly used as housekeeping genes, 
such as  18S amplicons (personal observations). For protein extraction, medium is 
discarded and cells are scraped in a lysis buffer such as RIPA (radioimmunopre-
cipitation assay) and then sonicated. As much as 100 μg of protein per well can be 
collected from a 12-well plate. 
21.8  Conclusions 
 Since the original generation of the GLUTag cell line in 1994 by Drucker, 
Brubaker and colleagues, these cells have been instrumental in the studies address-
ing the role of nutrients in L-cell physiology, and particularly in GLP-1 secretion. The 
easy maintenance of the cells, their close similarity in phenotype with non-immortal-
ized L-cells and the ability to apply advanced techniques such as patch-clamp record-
ing and gene silencing are clear advantages for the use of this cell line. Yet, as is 
common for many tumoural cell lines, some phenotypic differences are found between 
GLUTag cells and the normal L-cell, notably, the former presenting a higher diversity 
of glucose-sensing mechanisms and, apparently, insensitivity to SCFAs. Nevertheless, 
the use of GLUTag cells has been crucial to develop potential novel therapies for 
diabetes, such as GPR119 agonists. It is highly likely that GLUTag cells will continue 
to be intensively used as a model of the enteroendocrine L-cell until the isolation of 
primary L-cells becomes an easier and more standardized procedure. 
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